Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Final paper now out in Blood Neoplasia for our ph 1-2 program Tagraxofusp in chronic myelomonocytic leukemia.”
Title: Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study
Authors: Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia-Manero
Read the Full Article on Blood Neoplasia
More posts featuring Tagraxofusp.
